A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
This protocol presents a novel approach to alleviating the symptoms and improving the quality of life of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) by employing moving cupping along meridians therapy to stimulate the first sideline of the bladder meridian.
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition characterized by persistent and progressive airflow obstruction, resulting in chronic respiratory symptoms like dyspnea, cough, and sputum production, accompanied by wheezing, chest tightness, fatigue, and reduced physical activity. Under the influence of various factors, patients with COPD often experience acute exacerbations, which have a significant negative impact on the prognosis, quality of life, and life span of patients. As a branch of cupping therapy, moving cupping along meridians is an essential complementary therapy of the traditional Chinese medicine system. Cupping plays a unique role in treating and preventing many diseases by stimulating the local skin with negative pressure.
This article elaborately describes the procedure of moving cupping along meridians therapy in the treatment of AECOPD. The effectiveness and feasibility of moving cupping along meridians therapy in relieving symptoms and enhancing the quality of life is demonstrated by comparing the changes in the 36-item Short-Form (SF-36) health survey questionnaire, the modified Medical Research Council dyspnea scale (mMRC), and the COPD Assessment Test (CAT) score before and after the treatment. As a cost-effective complementary treatment, the protocol for the moving cupping along meridians treatment described in this article is expected to provide a reference for non-pharmacological treatment options for AECOPD.
Chronic obstructive pulmonary disease (COPD) is a prevalent, preventable, and treatable heterogeneous lung disease characterized by persistent, often progressive airflow obstruction resulting from abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema). It manifests chronic respiratory symptoms such as dyspnea, cough, expectoration, along with wheezing, chest tightness, fatigue, and reduced activity levels. Some patients may also experience acute exacerbations characterized by increased respiratory symptoms, which can impact their physical condition and prognosis, necessitating specific prevention and therapeutic measures1.
According to the Global Burden of Disease Study by the World Health Organization (WHO) and the Burden of Obstructive Lung Diseases (BOLD) project, the prevalence of COPD worldwide is 10.3%, leading to approximately 3 million deaths annually, making COPD the third leading cause of mortality globally2,3,4. In China, data from a nationwide cross-sectional study indicates an 8.6% prevalence of COPD, with a striking 13.7% prevalence among people over 40 years old. A considerable proportion of patients have not received timely diagnosis and treatment, which severely impacts public health5.
With the increase in smoking rates in low- and middle-income countries and the exacerbation of population aging in high-income countries, the burden of COPD is anticipated to escalate. Estimates suggest that by 2060, COPD and related diseases will claim the lives of more than 5.4 million people annually, resulting in significant economic and social burdens, including direct and indirect treatment costs. Similarly, productivity loss and premature retirement caused by the disease are also considered the main sources of indirect costs of the disease6,7.
An acute exacerbation of COPD (AECOPD) is defined as a transient worsening of dyspnea, cough, and expectoration production lasting less than 14 days, often triggered by local and systemic inflammation caused by airway infection, pollution, or other lung injuries8. A population-based survey conducted in nine Asia-Pacific regions showed that 46% of patients with COPD had at least one acute exacerbation in the previous year, and 19% of patients required hospitalization9.
It is worth noting that COPD has imposed considerable costs on the healthcare system, mainly related to the moderate to severe stage and complications. A systematic review of COPD cost analysis reveals that AECOPD treatment costs significantly contribute to overall treatment expenses7. Current management strategies for acute exacerbations involve pharmacological and non-pharmacological interventions aimed at alleviating airway obstruction, combating infections, and enhancing oxygenation. However, they are still facing challenges like rising drug resistance and airway microbiome disturbances10.
Cupping therapy is an ancient traditional Chinese medicine technique with a history spanning thousands of years. Much like acupuncture, it is an essential component of complementary and alternative medicine worldwide11. Cupping therapy is a non-pharmacological external treatment method that uses plastic, bamboo, or glass cups as tools. By utilizing methods such as burning, suction, or steam to create negative pressure within the cup, the cups are able to adsorb onto specific points on the body's surface, acupoints, or meridians, which can stimulate subcutaneous tissues, promoting congestion and blood stasis in the local skin, thereby achieving the goal of preventing and treating diseases12. Moving cupping along meridians is a branch of the cupping method based on the meridian theory of acupuncture and moxibustion. Through the application of flame, the cup adheres to the skin, and with the aid of glycerin, it repeatedly moves along the pathways of the meridians, resulting in benign stimulation13.
This article elaborates on the operation steps, key points, and precautions of moving cupping along meridian therapy for AECOPD, including patient qualification assessment, medical equipment used, treatment site, course of treatment, posttreatment care, and adverse reaction response measures. The study employed the medical outcomes study 36-item short form (SF-36) health survey questionnaire, the modified Medical Research Council dyspnea scale (mMRC), and the COPD Assessment Test (CAT) score as efficacy evaluation indicators. The efficacy of this protocol can be assessed by comparing the scores of patients before and after treatment. With the advantages of definite curative effect, low cost, and easy acceptance by middle-aged and elderly patients, moving cupping along meridians therapy shows the potential to offer a new direction for non-pharmacological treatment of AECOPD.
This study is a before-and-after self-controlled trial with patients sourced from the People's Hospital of Xinjin District, Chengdu. Operators participating in the trial must hold qualifications as traditional Chinese medicine practitioners and have independently conducted clinical treatments for over 1 year. All of the manipulation techniques followed the national standardized manipulations of acupuncture and moxibustion - Part 5: Cupping therapy14 to ensure the specification and correctness of the manipulations. This study has been approved by the Ethics Committee of People's Hospital of Xinjin District, Chengdu (No. 2023-10). Patients were informed of the purpose and method of treatment and provided consent for the utilization of images generated during the trial for research purposes.
1. Pretreatment evaluation
2. Preparation before operation
3. Procedure
NOTE: Course of treatment: once every 7 days, three treatments in total. Any adverse reactions observed in patients must be promptly managed and documented, and with reassessment conducted post-remission.
4. Posttreatment care
5. Data processing
This paper describes a self-controlled before-and-after trial to investigate the efficacy of cupping therapy in relieving symptoms and improving the quality of life of AECOPD patients. In this study, a total of five eligible patients participated in the trial. The data were derived from questionnaires completed by patients before and after treatment.
The medical outcomes study 36-item short form (SF-36) health survey questionnaire, the COPD Assessment Test (CAT), and the modified Medical Resea...
Modern medical treatment strategies for AECOPD typically involve pharmacological interventions and respiratory support with a wide range of pharmacological interventions such as bronchodilators, various antibiotics, and oral and intravenous corticosteroids16. Even though there is high-level evidence supporting the use of antibiotics and oral/intravenous corticosteroids in improving outcomes such as recurrence rates, mortality rates, and duration of hospital stay, recent studies have indicated that...
The authors have no conflicts of interest to disclose.
This research was supported by the 2022 "Tianfu Qingcheng Plan" Tianfu Science and Technology Leading Talents Project (Chuan Qingcheng No. 1090); The National TCM Clinical Excellent Talents Training Program (National TCM Renjiao Letter [2022] No. 1); "100 Talent Plan" Project of Hospital of Chengdu University of Traditional Chinese Medicine (Hospital office [2021] 42); Special subject of scientific research of Sichuan Administration of Traditional Chinese Medicine (2021MS539, 2023MS608); Sichuan Science and Technology Program (2023ZYD0050); and Medical research subject of Chengdu Health Commission (NO: 2022337).
Name | Company | Catalog Number | Comments |
95% alcohol | Sichuan Yijie Medical Technology Co., LTD | 20190079 | |
absorbent cotton ball | Cofoe Medical Technology Co.,Ltd | 20222140061 | |
glass cup | Cofoe Medical Technology Co.,Ltd | 20150041 | |
hemostatic forceps | Shanghai MEDICAL Instruments (GROUP) Co., Ltd | 20222201228 | |
medicinal glycerin | Henan Huakai Biotechnology Co., LTD | 20231002 |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved